Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Sciré AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, Cohen D, Saul A, Gerke C, Podda A. Launay O, et al. Among authors: gerke c. EBioMedicine. 2017 Aug;22:164-172. doi: 10.1016/j.ebiom.2017.07.013. Epub 2017 Jul 15. EBioMedicine. 2017. PMID: 28735965 Free PMC article. Clinical Trial.
The transfer and decay of maternal antibody against Shigella sonnei in a longitudinal cohort of Vietnamese infants.
Thompson CN, Le TP, Anders KL, Nguyen TH, Lu LV, Nguyen VV, Vu TD, Nguyen NM, Tran TH, Ha TT, Tran VT, Pham VM, Tran do HN, Le TQ, Saul A, Martin LB, Podda A, Gerke C, Thwaites G, Simmons CP, Baker S. Thompson CN, et al. Among authors: gerke c. Vaccine. 2016 Feb 3;34(6):783-90. doi: 10.1016/j.vaccine.2015.12.047. Epub 2015 Dec 29. Vaccine. 2016. PMID: 26742945 Free PMC article.
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Launay O, Artaud C, Lachâtre M, Ait-Ahmed M, Klein J, Luong Nguyen LB, Durier C, Jansen B, Tomberger Y, Jolly N, Grossmann A, Tabbal H, Brunet J, Gransagne M, Choucha Z, Batalie D, Delgado A, Müllner M, Tschismarov R, Berghmans PJ, Martin A, Ramsauer K, Escriou N, Gerke C. Launay O, et al. Among authors: gerke c. EBioMedicine. 2022 Jan;75:103810. doi: 10.1016/j.ebiom.2021.103810. Epub 2022 Jan 16. EBioMedicine. 2022. PMID: 35045362 Free PMC article. Clinical Trial.
High yield production process for Shigella outer membrane particles.
Berlanda Scorza F, Colucci AM, Maggiore L, Sanzone S, Rossi O, Ferlenghi I, Pesce I, Caboni M, Norais N, Di Cioccio V, Saul A, Gerke C. Berlanda Scorza F, et al. Among authors: gerke c. PLoS One. 2012;7(6):e35616. doi: 10.1371/journal.pone.0035616. Epub 2012 Jun 6. PLoS One. 2012. PMID: 22701551 Free PMC article.
An O antigen capsule modulates bacterial pathogenesis in Shigella sonnei.
Caboni M, Pédron T, Rossi O, Goulding D, Pickard D, Citiulo F, MacLennan CA, Dougan G, Thomson NR, Saul A, Sansonetti PJ, Gerke C. Caboni M, et al. Among authors: gerke c. PLoS Pathog. 2015 Mar 20;11(3):e1004749. doi: 10.1371/journal.ppat.1004749. eCollection 2015 Mar. PLoS Pathog. 2015. PMID: 25794007 Free PMC article.
Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants.
Rossi O, Pesce I, Giannelli C, Aprea S, Caboni M, Citiulo F, Valentini S, Ferlenghi I, MacLennan CA, D'Oro U, Saul A, Gerke C. Rossi O, et al. Among authors: gerke c. J Biol Chem. 2014 Sep 5;289(36):24922-35. doi: 10.1074/jbc.M114.566570. Epub 2014 Jul 14. J Biol Chem. 2014. PMID: 25023285 Free PMC article.
65 results